Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, has granted significant equity incentives to its new Chief Development Officer, Dr. Qing Zuraw. The compensation package includes 4,373,040 stock options at an exercise price of $2.38 per share and 937,080 restricted stock units (RSUs).
The grants, effective July 17, 2025, were made under the Vor Biopharma Inc. 2023 Inducement Plan as a material inducement to employment, complying with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term with a four-year vesting schedule, while RSUs will vest quarterly over four years, starting August 1, 2026.
Vor Bio (Nasdaq: VOR), una società biotecnologica in fase clinica, ha concesso importanti incentivi azionari al suo nuovo Chief Development Officer, il Dr. Qing Zuraw. Il pacchetto retributivo comprende 4.373.040 opzioni su azioni con un prezzo di esercizio di 2,38 dollari per azione e 937.080 unità azionarie vincolate (RSU).
Le concessioni, efficaci dal 17 luglio 2025, sono state effettuate nell'ambito del Vor Biopharma Inc. 2023 Inducement Plan come incentivo materiale all'assunzione, in conformità con la Regola 5635(c)(4) del Nasdaq. Le opzioni su azioni hanno una durata di 10 anni con un piano di maturazione quadriennale, mentre le RSU matureranno trimestralmente nell'arco di quattro anni, a partire dal 1° agosto 2026.
Vor Bio (Nasdaq: VOR), una empresa biotecnológica en etapa clínica, ha otorgado incentivos significativos en acciones a su nuevo Director de Desarrollo, el Dr. Qing Zuraw. El paquete de compensación incluye 4.373.040 opciones sobre acciones con un precio de ejercicio de 2,38 dólares por acción y 937.080 unidades restringidas de acciones (RSU).
Las concesiones, vigentes desde el 17 de julio de 2025, se realizaron bajo el Plan de Incentivos 2023 de Vor Biopharma Inc. como un incentivo material para el empleo, cumpliendo con la Regla 5635(c)(4) del Nasdaq. Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición de derechos de cuatro años, mientras que las RSU se adquirirán trimestralmente durante cuatro años, comenzando el 1 de agosto de 2026.
Vor Bio (나스닥: VOR)는 임상 단계의 바이오테크 회사로서, 신임 최고개발책임자(Chief Development Officer)인 Dr. Qing Zuraw에게 상당한 주식 인센티브를 부여했습니다. 보상 패키지에는 주당 행사 가격이 2.38달러인 4,373,040주 스톡 옵션과 937,080주 제한 주식 단위(RSU)가 포함되어 있습니다.
이 부여는 2025년 7월 17일자로 발효되었으며, Vor Biopharma Inc. 2023 유인 계획에 따라 고용 유인을 위한 중요한 조치로서 나스닥 상장 규칙 5635(c)(4)를 준수합니다. 스톡 옵션은 10년 만기이며 4년간 권리 취득 일정이 적용되고, RSU는 2026년 8월 1일부터 시작하여 4년에 걸쳐 분기별로 권리 취득됩니다.
Vor Bio (Nasdaq : VOR), une société biotechnologique en phase clinique, a accordé d'importantes incitations en actions à son nouveau directeur du développement, le Dr Qing Zuraw. Le package de rémunération comprend 4 373 040 options d'achat d'actions à un prix d'exercice de 2,38 $ par action ainsi que 937 080 unités d'actions restreintes (RSU).
Les attributions, effectives à compter du 17 juillet 2025, ont été réalisées dans le cadre du Plan d'incitation 2023 de Vor Biopharma Inc. en tant qu'incitation matérielle à l'emploi, conformément à la règle 5635(c)(4) du Nasdaq. Les options d'achat ont une durée de 10 ans avec un calendrier d'acquisition des droits sur quatre ans, tandis que les RSU seront acquises trimestriellement sur quatre ans, à partir du 1er août 2026.
Vor Bio (Nasdaq: VOR), ein Biotechnologieunternehmen in der klinischen Phase, hat seinem neuen Chief Development Officer, Dr. Qing Zuraw, bedeutende Aktienanreize gewährt. Das Vergütungspaket umfasst 4.373.040 Aktienoptionen mit einem Ausübungspreis von 2,38 USD pro Aktie sowie 937.080 Restricted Stock Units (RSUs).
Die Zuteilungen, wirksam ab dem 17. Juli 2025, wurden im Rahmen des Vor Biopharma Inc. 2023 Inducement Plans als wesentlicher Anreiz zur Einstellung gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Zeitplan, während die RSUs vierteljährlich über vier Jahre ab dem 1. August 2026 vesten.
- None.
- None.
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company’s Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term and an exercise price of
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Investor Contacts:
Sarah Spencer
+1 857-242-6076
investors@vorbio.com
Carl Mauch
investors@vorbio.com
FAQ
What equity compensation did Vor Bio (VOR) grant to its new Chief Development Officer?
What is the vesting schedule for Vor Bio's (VOR) stock options granted to Dr. Zuraw?
What is the exercise price of the stock options granted by Vor Bio (VOR)?
When do the RSUs granted by Vor Bio (VOR) begin vesting?
